Sharon Osbourne, Colon Cancer, and Why Screening Matters

The part of the story that is on the record

The BBC reported in 2012 that Sharon Osbourne had been diagnosed with colon cancer in 2002. The same report noted that in 2004 she set up a cancer foundation with Cedars-Sinai Hospital in Los Angeles, to support people with colon cancer who could not afford health care.

That is the public record. Her treatment decisions and her medical details are hers, and this article does not go looking for them. What is worth several hundred more words is the disease, because colorectal cancer is unusual among cancers. It is one of the very few that screening can prevent outright rather than merely catch early.

A cancer that announces itself years in advance

Most colorectal cancers start as a polyp. A polyp is a small growth on the inner lining of the colon or rectum. The National Cancer Institute is direct about the consequence: finding and removing polyps can prevent colorectal cancer.

Think about what that means. In most cancers, screening finds disease that already exists and hopes to find it small. In colorectal cancer, screening can find the thing that would have become cancer and take it out in the same appointment. The tumor never happens.

Not every polyp turns into cancer, and the ones that do usually take years. That slow window is the entire opportunity.

The screening menu, with real intervals

The U.S. Preventive Services Task Force issued its current recommendation on May 18, 2021. It grades screening as follows: an A for adults aged 50 to 75, a B for adults aged 45 to 49, and a C for adults aged 76 to 85, meaning selective screening based on individual circumstances.

There is more than one acceptable test. USPSTF lists these strategies and intervals:

• High-sensitivity guaiac fecal occult blood test, or fecal immunochemical test (FIT), every year.
• Stool DNA-FIT every one to three years.
• Computed tomography colonography every five years.
• Flexible sigmoidoscopy every five years.
• Flexible sigmoidoscopy every ten years, plus a FIT every year.
• Colonoscopy every ten years.

The best test is a real one that gets done. A stool test done every year beats a colonoscopy that keeps getting postponed. One thing to know in advance: if a stool test comes back positive, a colonoscopy follows. The stool test is a filter, not a final answer.

Symptoms that should not wait for the next screening

Screening is for people with no symptoms. Symptoms are a different conversation and move faster. NCI lists these signs of colon cancer:

• Blood in the stool, either bright red or very dark.
• A change in bowel habits, including diarrhea, constipation, or stools that become narrow.
• Abdominal discomfort that does not settle.
• Unexplained weight loss.
• Fatigue.
• Vomiting.

Blood is the one people talk themselves out of. Hemorrhoids are common, and hemorrhoids do bleed. But hemorrhoids and a tumor can exist in the same person, and only one of them can be ruled out by looking. Any visible rectal bleeding deserves an explanation from a clinician, not from the internet, and not at any particular age.

A useful rule: a change in bowel habits that has lasted more than a few weeks, with no clear cause, is worth a call. So is unexplained tiredness paired with any bleeding, because slow blood loss quietly drains iron.

Who is at higher risk

NCI lists the main risk factors for colon cancer. Older age is the largest. Others include a family history of colorectal cancer, a personal history of colon or rectal cancer or of high-risk adenomas, and inherited conditions such as familial adenomatous polyposis and Lynch syndrome.

Chronic ulcerative colitis or Crohn disease lasting eight years or longer raises risk. So do heavy alcohol use, smoking, and obesity. NCI also lists being Black as a risk factor, which reflects differences in incidence and outcomes in United States data.

If a parent, sibling, or child had colorectal cancer, that is a reason to ask about starting screening earlier than 45.

What happens once something is found

NCI describes the workup. A digital rectal exam and stool blood testing may come first. Colonoscopy is the test that sees the whole colon, using a thin lighted tube passed through the rectum. Anything suspicious is biopsied, and that tissue is examined for cancer and for signs of Lynch syndrome.

A blood test for carcinoembryonic antigen, or CEA, is often drawn. It is not a screening test. NCI's clinician guidance notes that a high pretreatment CEA carries negative prognostic significance. Staging then uses CT, MRI, PET, chest imaging, and lymph node sampling.

Most colon cancers are adenocarcinomas, meaning they arise from glandular lining cells. NCI lists other histological types too, including mucinous, signet ring and neuroendocrine tumors. Of these, tumors with neuroendocrine differentiation typically carry a poorer prognosis than pure adenocarcinoma variants.

What treatment involves

NCI states that surgery is the primary treatment and results in cure in roughly 50% of patients. The surgeon removes the segment of bowel containing the tumor along with nearby lymph nodes.

One quality marker is easy to remember and worth asking about. NCI recommends that at least 12 lymph nodes be examined to confirm that nodes are clear. Fewer than that, and a "node-negative" result is less trustworthy.

The pathology report then drives what comes next. Cancer found in lymph nodes usually means chemotherapy after surgery. Two molecular findings matter. Microsatellite instability, a pattern caused by faulty DNA mismatch repair, has been associated with improved survival independent of stage. It also changes drug selection.

Numbers that describe a population

For 2026 the American Cancer Society expects 158,850 new colorectal cancers in the United States, about 7.5% of all new cancers, and 55,230 deaths; SEER, the federal cancer statistics program, reprints those figures. The Society's 2025 split, carried in NCI's clinician summary, was 107,320 colon cases and 46,950 rectal cases.

Stage drives outcome. Among people diagnosed from 2016 through 2022, SEER records five-year relative survival of 91.3% when colorectal cancer is still localized, 75.2% once it has reached regional lymph nodes, and 16.9% once it has spread to distant organs. Only about 34% are caught while localized. Roughly 23% are already distant at diagnosis.

Those are group figures across tens of thousands of people. They do not describe any individual, and they say nothing about how one person will do. What they do show is the value of the appointment that finds a polyp before it becomes any of these numbers at all.

Sources

• NCI: Colon Cancer Treatment (PDQ) — Health Professional Version
• NCI: Colon Cancer Treatment (PDQ) — Patient Version
• SEER Cancer Stat Facts: Colorectal Cancer
• USPSTF: Colorectal Cancer Screening, final recommendation, May 18, 2021
• BBC News: Sharon Osbourne has double mastectomy over cancer fears
• American Cancer Society: Cancer Facts & Statistics